摘要
1目的 探讨镁在新生儿低氧缺血性脑损伤中的治疗价值。 2方法 采用随机对照法 ,对 76例新生儿缺氧缺血性脑病 (HIE)进行治疗研究 ,对照组 38例给予一般常规综合治疗 ,治疗组 38例在此基础上每天加用2 5 0 g/ L硫酸镁注射液 0 .1m L / kg体质量。3结果 治疗组治疗后临床症状消失时间为 (3.8± 1.3) d,对照组 (6 .2±1.7) d,两组比较差异有极显著意义 (t=6 .6 7,P <0 .0 1) ;治疗组治疗后 10 d脑 CT检查脑组织恢复正常率为47.2 % ,明显高于对照组的 2 2 .8% ,差异有显著性 (χ2 =4.6 2 ,P<0 .0 5 ) ;治疗组血清肌酸激酶脑型同工酶 (CK- BB)活性为 (6 .2 1± 1.83) U/ L ,对照组为 (11.2 6± 2 .14) U / L ,两组比较差异有极显著性 (t=10 .74,P<0 .0 1) ;血清钙、镁浓度治疗组分别为 (2 .16± 0 .2 4) m mol/ L ,(0 .91± 0 .13) m mol/ L ,对照组为 (1.82± 0 .2 1) mmol/ L ,(0 .6 8± 0 .12 )mm ol/ L ,两组比较差异有极显著性 (t=6 .42 ,7.72 ,P<0 .0 1)。治疗组无 1例出现硫酸镁不良反应。 4结论 小剂量硫酸镁治疗 HIE是一简便、安全。
Objective\ To evaluate the effects of magnesium sulfate on neonatal hypoxic ischemic encephalopathy (HIE). Methods\ 76 patients with neonatal HIE were randomly divided into two groups. Control group: 38 cases were treated with general therapy only. Treatment group: 38 cases were treated with general therapy and 250g/L magnesium sulfate 0.1mL/kg intravenous drip.\ Results\ The period of relieving the clinical symptoms in the treatment group was significantly shorter than that of the control group (3.8±1.3) days vs (6.2±1.7) days ( t=6.67, P <0.01). After 10 days of treatment, the recovery rate of brain CT in the treatment group was significantly higher than that of the control group (47.2% vs 22.8%, χ 2=4.62, P <0.05). The activity of serum creatine phosphokinase BB between the treatment group and the control group was significantly different( 6.21 ± 1.83 )U/L vs (11.26±2.14)U/L ( t=10.74, P< 0.01). The concentration of serum magnesium and calcium was statistically different between the treatment group and the control group (2.16±0.24)mmol/L vs (1.82±0.21)mmol/L, (0.91±0.13)mmol/L vs (0.68±0.12)mmol/L ( t= 6.42 , 7.72, P <0.01). No side effects were found in the treatment group.\ Conclusion A small dose of magnesium sulfate is safe and effective medicine for neonates with HIE. [
出处
《齐鲁医学杂志》
2000年第2期90-92,共3页
Medical Journal of Qilu
关键词
缺氧缺血性脑病
硫酸镁
新生儿
疗效
hypoxic ischemic encephalopathy
magnesium sulfate
infant, newborn
therapeutics